KRAS and neoplasm: In agreement with the above results, we found that XIAP expression was lower in RAS wild‐type HEK293A and HeLa cells and was significantly higher in RAS‐mutant cells, particularly in KRAS‐mutant tumor cells (Figure 1I), suggesting that targeting XIAP could also affect the course of KRAS‐related diseases.